REDWOOD CITY, Calif., Feb. 28 /PRNewswire/ -- FoxHollow Technologies, Inc. , which develops and markets endovascular therapeutic devices for the treatment of peripheral artery disease (PAD), today announced the hiring of Kevin Cordell as the company’s new Senior Vice President of Global Sales.
In his new role, Mr. Cordell will lead FoxHollow’s worldwide sales organization, focusing and executing on corporate strategies for the growth and expansion of FoxHollow’s current product lines as well as the expansion of the company’s product portfolio with the integration of potential future product acquisitions.
“We are excited to welcome Kevin Cordell to FoxHollow’s senior management team. Kevin brings to us an incredible depth of sales leadership experience, which is vital to both the achievement of our revenue goals and our long-term growth as a market leader in vascular technologies,” noted Duke Rohlen, President of Strategic Operations. “Kevin has a proven track record of success in the interventional cardiovascular space, and we are delighted to have him on FoxHollow’s leadership team as we continue to execute on our recently-outlined corporate strategy,” Rohlen continued.
Mr. Cordell joins FoxHollow with over 12 years of experience in the pharmaceutical, biotech and medical device industries. Most recently, Mr. Cordell served as Vice President of Sales, from 2005 to the present for Cordis Cardiology, a Johnson & Johnson Company specializing in medical devices for vascular intervention. Specifically, over the last four years, he led U.S. sales in the highly competitive coronary stent market.
“I am already impressed with FoxHollow’s strong commitment to helping physicians and improving patient outcomes, and I am excited to join the company and continue these efforts,” commented Mr. Cordell. “I am very enthusiastic about the opportunity to work with FoxHollow’s market-leading sales organization as the company launches new products, advances clinical programs, and broadens the product portfolio, with the mission of becoming a leading vascular solutions company,” added Cordell.
Mr. Cordell joined Cordis Cardiology in 2003 as Executive Sales Director and was a board member of the company. Prior to working at Cordis, he held various sales and marketing positions at Centocor, Inc., a subsidiary of Johnson & Johnson, focusing on the development of biomedicines to treat immune disorders. He began his sales career in 1993 at Boehringer Mannheim Corporation, a wholly-owned subsidiary of the Roche Corporation. Mr. Cordell holds a Bachelor of Business Administration from the University of Oklahoma.
About FoxHollow Technologies, Inc.
FoxHollow Technologies, Inc. develops and markets endovascular therapeutic devices for the treatment of peripheral artery disease (PAD). PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company’s SilverHawk(R) Plaque Excision System is a minimally invasive method of removing obstructive plaque and restoring blood flow to the legs and feet. The company’s Rinspirator(R) System removes thrombus, or blood clots, from occluded arteries in patients suffering from PAD or coronary artery disease (CAD). For more information, please visit our website at http://www.foxhollowtech.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding FoxHollow’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Specifically, expectations regarding future product releases and acquisitions are forward-looking statements involving risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included under the caption, “Factors Affecting Future Operating Results,” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our most recent quarterly report on Form 10-Q for the quarter ended September 30, 2006 filed with the SEC on November 9, 2006, and available on our investor relations website at http://investor.foxhollowtech.com and on the SEC’s website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. FoxHollow undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Contacts: Matt Ferguson Chief Financial Officer 650-421-8449 investorrelations@foxhollowtech.com Robin Gaffney Media Relations 650-421-8614 rgaffney@foxhollowtech.com
FoxHollow Technologies, Inc.
CONTACT: Matt Ferguson, Chief Financial Officer, +1-650-421-8449, orinvestorrelations@foxhollowtech.com, or Robin Gaffney, Media Relations,+1-650-421-8614, or rgaffney@foxhollowtech.com, both of FoxHollowTechnologies, Inc.
Web site: http://www.foxhollowtech.com//
